Drug Trial Radar · NCT07087795
A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Jul 1, 2025
Primary completion
Sep 12, 2026
Study completion Sep 25, 2026
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jul 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is testing the effect of a new study medicine NNC0194-0499 in type 1 diabetes. The purpose of the study is to compare the effect of NNC0194-0499 on the blood sugar levels of participants with type 1 diabetes when taken in combination with semaglutide or placebo. All participants will receive standard of care insulin treatment. The study will last for about 36 weeks.
Conditions
- Diabetes Mellitus, Type 1
Interventions
NNC0194-0499Drug
Participants will receive subcutaneous NNC0194-0499 once weekly.
PlaceboDrug
Participants will receive placebo matched to NNC0194-0499 subcutaneously.
SemaglutideDrug
Participants will receive subcutaneous semaglutide once weekly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Change in time in range (TIR) 3.9-10.0 mmol/L (70-80 mg/dL)Time frame: From baseline (day -14 - -1) to day 36-49 / day 106-119
- Part B: Change in time in range (TIR) 3.9-10.0 mmol/L (70-80 mg/dL)Time frame: From baseline (day -14 - -1) to day 92-105 / day 162-175
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Profil Institut für Stoffwechselforschung GmbH
Neuss, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.